Inko Nimmrich

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

Jens Huober, Peter A. Fasching, M. Barsoum et al. · The Breast · 2011 · 226 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer

John W.M. Martens, Inko Nimmrich, Thomas Koenig et al. · Cancer Research · 2005 · 153 citations

Medicine, Genetics, Oncology +17

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group

Sabine Maier, Inko Nimmrich, Thomas Koenig et al. · European Journal of Cancer · 2007 · 114 citations

Medicine, Molecular Genetics, Oncology +17

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients

Inko Nimmrich, Anieta M. Sieuwerts, Marion E. Meijer‐van Gelder et al. · Breast Cancer Research and Treatment · 2007 · 107 citations

Medicine, Molecular Biology, Oncology +11

Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing <i>PITX2</i> DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients

Nadia Harbeck, Inko Nimmrich, Arndt Hartmann et al. · Journal of Clinical Oncology · 2008 · 101 citations · Full text

Medicine, Molecular Biology, Oncology +17